38.3004.20% ( -1.680 )
Delay Closed: Nov 17, 16:08:15Valuation
Current ValuationThe current P/E ratio is 39.55, within the reasonable range, cheaper than 54.73% of the time in the past 3 years, and the industry ranks 19/78, the industry Median -4.90.
39.55xP/E
HK$38.30Stock price
HK$0.97Earnings per share
39.55xP/E
Stock priceHK$38.30Earnings per shareHK$0.97
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 56.62x
- Typical range
- -9.22x–132.55x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0150300450600
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
02315HKBIOCYTOGEN-B | 39.55x | 108.67% | HK$17.12B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
